Moving toward a Different Translational Research Paradigm
Moving toward a different translational research paradigm
Advances in technology have enabled pharmaceutical companies to move toward more accurate methods in preclinical drug safety work.
To slow the ever-increasing development costs of drug pipelines — which today total roughly $2.6 billion for every drug brought to market — the industry must remove potentially unsafe candidates during preclinical trials. Yet too often, in vitro and in vivo models have fallen short as predictors of a drug’s success in humans. However, thanks to new gene-editing tools and ways of handling cells, this process can become more reliable.
Perhaps the most promising changes are in disease modeling. The quality of data and lack of capabilities to integrate information from disparate sources were limiting factors for in silico modeling in the past. However, new approaches have made it possible to see past the data bottleneck, promising reliable, flexible and accurate methods for predicting drug safety.
This white paper focuses on how in vitro, in vivo and in silico drug safety predictions are changing as the industry moves toward a new paradigm.
To access the complimentary white paper 'Moving toward a Different Translational Research Paradigm', please fill in the form below.
Elsevier's R&D Solutions supporting 'Moving toward a Different Translational Research Paradigm'
Enable better informed preclinical drug safety decisions with comprehensive, fully searchable FDA/EMA drug approval documents and comparative extracted drug safety data.
Learn more about PharmaPendium